Orthopediatrics Corp. · NASDAQ:KIDS
Orthopediatrics — Investor Presentation (August 2026)
33 slides from Orthopediatrics's investor presentation, August 2026
Slide 1: 2026 Investor Presentation
2026 Investor Presentation www.OrthoPediatrics.com
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, op
Slide 3: Founded on the cause of impacting children with orthopedic conditions
OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions + 1,382,000 pediatric patients treated since inception 1 2026 // 3
Slide 4: Historical Challenges of Pediatric Orthopedics
Historical Challenges of Pediatric Orthopedics Re-Purposed Adult Plate Screws through growth plate 01 Children’s unique clinical conditions 02 Existing solutions are re-purposed from adult implants 03 Limited development of new technologies 04 No specialized sales force in Pediatric Orthopedics 05 L
Slide 5: OrthoPediatrics Solution
OrthoPediatrics Solution PediLoc Femur Screws parallel to growth plate 01 Product development focused exclusively on pediatric patients 02 Broadest pediatric specific portfolio in the industry 03 Delivering first in market novel surgical solutions 04 Only global commercial channel to market 05 Leadi
Slide 6: Only Focused Pediatric Orthopedic Company
Only Focused Pediatric Orthopedic Company +90 unique pediatric systems Innovative Consistent cadence of innovative product launches Technology Expanding suite of enabling technologies Internal R&D, acquisitions, and partnerships Only global sales & distribution channel Consistent Commercial Serve 10
Slide 7: U.S. Addressable Market $2.8B
Total Global Addressable Market – $6.2B U.S. Addressable Market1 — $2.8B Competitive Dynamics $500 Enabling $610M 01 Large incumbents repurpose adult implants Technology Trauma & Deformity Correction 02 Require specialized sales force Implants $165M 03 Lack of focus on pediatric conditions Growing I
Slide 8: Strategic Pillars
Strategic Pillars Laser focus on high-volume Children’s Hospitals that treat majority of 01 pediatric patients 02 Provide a broad product portfolio uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs 03 Deploy instrument sets and provide unparalleled sale
Slide 9: Current U.S. Target Market $1.6B
01 Focus on High-Vol Children’s Hospitals Current US Target Market – $1.6B Current U.S. Target Market1 — $1.6B $300M Enabling Tech $455M Trauma, Deformity Correction & Sports Medicine Implants Comments 01 ~1,520 Fellowship Trained Pediatric Surgeons $500M 02 Majority of Pediatric Centers are Teachin
Slide 10: 20 Years of Foundation Building
02 Provide Broad Product Portfolio A History of Steady Innovation in Pediatrics 20 Years of Foundation Building 90+ Systems LAUNCH LAUNCH LAUNCH LAUNCH ACQUIRE ACQUIRE Broadest Portfolio across: Trauma & Def Scoliosis PediNail Orthex® MD Cannulated Hip Systems RESPONSE Sports Med System External Ort
Slide 11: Provide a Broad Product Portfolio: Strong Foundation of Implants
02 Provide a Broad Product Portfolio Strong Foundation of Implants 2026 // 11
Slide 12: Strong Innovation & R&D
02 Provide a Broad Product Portfolio Strong Innovation & R&D Surgeon-led Innovation Trauma & Deformity • New products originate 3P Small | Mini PNP | Retro from unmet clinical needs identified by pediatric orthopedic surgeons 3P | Knee PNP | SD Building Platforms Pin to Bar Ex-Fix • Focus on platfor
Slide 13: Entering a Super-Cycle of Differentiated Product Launches
02 Provide Broad Product Portfolio Innovation RoadMap Entering a “Super-Cycle” of Differentiated Product Launches 3P Hip PNP | Tibia GIRO VERTEGLIDE Iota Motion Platform Launched Launched Launched Limited Limited Limited Response Rib Traxio Halo Playbook & Pelvic DF2® Gravity Surgical 2026 // 13
Slide 14: Entering a Super-Cycle of Differentiated Product Launches
02 Provide Broad Product Portfolio Innovation RoadMap Entering a “Super-Cycle” of Differentiated Product Launches 3P Small | PNP | SD eLLi Tractor Fix 3P | Knee Mini Q3 2026 Q4 2026 Q1 2027 Q2 2027 Q3 2027 Q4 2027 Predictive VerAxis Pin to Bar Ex- PNP | Retro Planning Scoliosis Fix 2026 // 14
Slide 15: Accelerating Sales Growth Post-IPO
03 Expand Instr. Sets & Sales Personnel Accelerating Sales Growth Post-IPO Through Strategic Investment and Innovation Total Revenue ($M) +20% CAGR $236.3 2016 2025 CAGR $204.7 U.S. Independent Sales Consultants 90 232 11% Instrument Set Deployments $7M $17 10% $148.7 Unique Pediatric Systems 17 87
Slide 16: Improving ROI on Sets Deployed
03 Expand Instr. Sets & Sales Personnel Increasing ROI Set Deployment Efficiencies Reducing set deployments as a percentage of revenue while continuing to take share $300 30% Improving ROI on Sets Deployed $250 25% Super Cycle Product Launches 01 • Products with defined clinical needs & $200 20% str
Slide 17: Strategic Acquisitions & Partnerships
04 Expand Market with M&A Strategic Acquisitions & Partnerships Partnership Acquisition 2017 2019 2020 2021 2022 2023 2024 2026 2026 // 17
Slide 18: Key Growth-Strategic Objectives
OPSB Key Growth-Strategic Objectives Aggressive market-based Accelerate R&D with Scale OPSB selling channel clinic expansion strategy increasing number of YoY and sales force – grow with launches current portfolio of products 18 new markets by 2027 Launch 4 products in 2024 Doubling size of the sale
Slide 19: OPSB Market Expansion
OPSB Market Expansion Pace of Market Expansion OPSB clinics +4 markets in 2025 expected to be in 27 +6 markets territories in 2027 in 2026 out of 80 +8 markets in 2027 target territories 2026 // 19
Slide 20: OPSB ROI and Timing for Clinic Expansion
OPSB ROI and Timing for Clinic Expansion Greenfield Acqui-Hire 1-4 Initial Investment $200k-$500k $500K-$1M Positive EBITDA by end Positive EBITDA by end of Clinics EBITDA Goal of first full year first full year per FCF Goal After first full year Within first year market ROI Goal Break even ROI by Y
Slide 21: OPSB Opportunity $2.2B
04 Expand Market with M&A OPSB Opportunity – $2.2B U.S. Potential Target Market 1 — $1.0B Levity Device for Gait Assist Motion Spine Assist Halo Devices Traction, Other Specialty 300 Solutions U.S. Pediatric Centers Dynamic Femur Fracture (DF2) Brace Specialty Fracture Casting Fixation Devices 2 02
Slide 22: Physician Education and Awareness
05 Train Next-Gen Surgeons Physician Education and Awareness Supporting more than 20 fellowships 01 OP Hands-on sales training and support • Annually invests 3% of sales on clinical education • Conducts >700 product/training sessions per year 02 Market development • Fosters early relationships with
Slide 23: Differentiated Pediatric Systems Driving Growth
>90 Differentiated Pediatric Systems Driving Growth Trauma & Deformity Scoliosis 2025 Revenue by Product Family Pediatric Systems Revenue Pediatric Systems Revenue 68 $166.3 17 $66.0 14 $26.8 3 $9.3 2016 2025 2016 2025 2016 2025 2016 2025 +19% CAGR +22% CAGR >4X Growth >6X Growth Trauma & Deformity
Slide 24: Strong History of Y/Y Growth
Strong History of Y/Y Growth ($M) 13% $267.0 15% $236.3 38% $204.7 22% 25% $148.7 38% $122.3 26% -2% $98.0 26% 22% $72.6 $71.1 20% $57.6 31% 21% $45.6 22% $37.3 58% $31.0 400% 137% 44% $19.6 $23.7 $7.1 $10.2 $16.1 $0.6 $3.0 1 2 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 20
Slide 25: Revenue Seasonality
Revenue Seasonality Seasonality Drives Stronger Performance in Summer Months and Holiday Periods 29% Revenue as % of Total Year 27% 27% 27% 27% 27% 26% 26% 25% 26% 26% 26% 26% 26% 25% 25% 22% 22% 22% 22% 21% 19% 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 2021 2022 2023 2024 20
Slide 26: Income Statement Summary
Income Statement Summary ($ in Millions) FY2023 FY2024 FY2025 2Q 2025 2Q 2026 Revenue $148.7 $204.7 $236.3 $61.1 $70.5 Growth % 22% 38% 15% 16% 15% Gross profit $111.3 $148.6 $172.7 $44.0 $52.4 Margin % 75% 73% 73% 72% 74% Operating expenses $138.0 $183.6 $211.9 $54.7 $56.4 Operating loss ($26.8) ($
Slide 27: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation ($ in Millions) Three Months Ended June 30, 2025 2026 Net loss ($7.1) ($7.2) Interest expense, net 1.1 2.5 Other expense (income), net (4.7) 0.3 Income tax charge - 0.3 Depreciation and amortization 5.1 5.7 Stock-based compensation 5.3 4.2 Restructuring charges 3.0 - T
Slide 28: Adjusted EPS Reconciliation
Adjusted EPS Reconciliation Three Months Ended June 30, 2025 2026 Loss per share, diluted (GAAP) ($0.30) ($0.30) Tariffs 0.03 0.01 Restructuring charges 0.13 - Acquisition related costs 0.02 0.03 Minimum purchase commitment cost 0.01 - Adjusted loss per share, diluted (non-GAAP) ($0.11) ($0.26) 2026
Slide 29: Free Cash Flow ($M)
Free Cash Flow ($M) Total Year Quarterly YTD $30 $15 $15 $10 $10 ($8.1) $20 ($15) ($3.1) $5 ($13.9) $5 ($22.2) ($42) $9 $10 $7 $15 $4 $4 $9 $0 $0 $0 $(3) $(5) $(5) $(8) ($5) ($5) $(17) $(7) ($10) $(21) ($10) ($10) $(13) $(12) ($20) $(13) ($15) ($15) $(18) ($30) ($20) ($20) ($40) $(30) ($25) ($25) ($
Slide 30: Balance Sheet
Balance Sheet ($ in Millions) As of June 30, 2026 Assets Liabilities Cash, cash equivalents & short-term $47.9 Accounts payable $22.2 investments Accounts receivable 61.0 Debt 99.6 Inventory (net) 137.6 Accrued comp. & other liab. 41.8 Other current assets 6.1 Acquisition pay. & cont. consideration
Slide 31: Full Year 2026 Guidance
Full Year 2026 Guidance ($ in Millions) 2026 Guidance FY2026 Revenue $265.0 to $269.0 Adjusted EBITDA ~$25.0 Free Cash Flow Breakeven Assumptions FY2026 2026 Total Revenue Growth % 12% to 14% Set Deployment ~$10.0 2026 // 31
Slide 32: Investment Summary
Investment Summary 01 Only diversified company focused exclusively on pediatric orthopedics 02 Large, underpenetrated market opportunity in pediatrics 03 Highly concentrated customer base with targeted commercial strategy 04 Broad product portfolio with innovative solutions 05 Only provider committe
Slide 33: 2850 Frontier Drive Warsaw, IN 465852 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302
2850 Frontier Drive Warsaw, IN 465852 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302 2026 // www.OrthoPediatrics.com
OrthoPediatrics — Investor Presentation (August 2026) on 6ix